Recovery · Next-Gen BPC

Pentadeca Arginate (PDA)

Pentadeca Arginate is a stabilized analog of BPC-157 with an arginate salt formulation, marketed as a longer-acting and more bioavailable alternative to standard BPC-157.

Category: Recovery & Healing Last updated 2026-06-19

Pentadeca Arginate (PDA) at a glance

Pentadeca Arginate is a stabilized analog of BPC-157 with an arginate salt formulation, marketed as a longer-acting and more bioavailable alternative to standard BPC-157. Mechanism: BPC-157 analog (arginate salt). Typical route: Subcutaneous, oral. FDA status: Not FDA-approved. Dispensed by peptide compounding pharmacies. Clinical-trial evidence is limited compared with the underlying BPC-157 literature; most of the evidence base is preclinical or anecdotal

Drug classBPC-157 analog (arginate salt)

Half-lifeLonger than standard BPC-157

RouteSubcutaneous, oral

Common dosing250-500 mcg/day

FDA statusNot approved

Available throughCompounding pharmacies

Mechanism of action

PDA shares BPC-157's proposed mechanism of action: promoting angiogenesis, modulating nitric oxide pathways, and accelerating soft-tissue repair. The arginate stabilization is intended to extend half-life and improve oral and subcutaneous bioavailability.

Dosing reference

Subcutaneous: 250-500 mcg once or twice daily, typically near the injury site. Oral: 500 mcg-1 mg daily for gut-related applications. Cycles are commonly 4-6 weeks on, with re-evaluation.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Dispensed by peptide compounding pharmacies. Clinical-trial evidence is limited compared with the underlying BPC-157 literature; most of the evidence base is preclinical or anecdotal.

U.S. telehealth providers that work with Pentadeca Arginate (PDA)

#1 of 4

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).

Read review →

#2 of 4

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).

Read review →

#3 of 4

Heally

70/100v3.0 six-pillar rubric

Starting at $110/mo. Heally is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).

Read review →

#4 of 4

PeterMD

71/100v3.0 six-pillar rubric

Starting at $125/mo. PeterMD is one of the providers covered in our editorial directory that dispenses or coordinates Pentadeca Arginate (PDA).

Read review →

Related recovery peptides

Browse the full Recovery & Healing category →

Frequently asked questions about Pentadeca Arginate (PDA)

How is PDA different from BPC-157?

Pentadeca Arginate is the same core 15-amino-acid sequence as BPC-157 with an arginate-salt modification intended to improve stability and bioavailability. In practice, claimed advantages over BPC-157 vary between manufacturers.

Is PDA safer than BPC-157?

There is no robust head-to-head safety data. Both are not FDA-approved; safety profiles in published preclinical work are similar.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing